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CLINICAL INVESTIGATIONS
Homocysteine Levels and Treatment Effect in the Prospective
Study of Pravastatin in the Elderly at Risk
Yvonne M. Drewes, MD,a Rosalinde K. E. Poortvliet, MD,a Jeanet W. Blom, MD, PhD,a
Wouter de Ruijter, MD, PhD,a Rudi G. J. Westendorp, MD, PhD,b David J. Stott, MD, PhD,c
Henk J. Blom, PhD,d Ian Ford, PhD,e Naveed Sattar, MD, PhD,f J. Wouter Jukema, MD, PhD,g
Willem J. J. Assendelft, MD, PhD,a,h Anton J. M. de Craen, PhD,b and Jacobijn Gussekloo, PhDa
OBJECTIVES: To assess the effect of preventive pravasta-
tin treatment on coronary heart disease (CHD) morbidity
and mortality in older persons at risk for cardiovascular
disease (CVD), stratified according to plasma levels of
homocysteine.
DESIGN: A post hoc subanalysis in the PROspective
Study of Pravastatin in the Elderly at Risk (PROSPER),
started in 1997, which is a double-blind, randomized, pla-
cebo-controlled trial with a mean follow-up of 3.2 years.
SETTING: Primary care setting in two of the three PROS-
PER study sites (Netherlands and Scotland).
PARTICIPANTS: Individuals (n = 3,522, aged 70–82,
1,765 male) with a history of or risk factors for CVD were
ranked in three groups depending on baseline homocyste-
ine level, sex, and study site.
INTERVENTION: Pravastatin (40 mg) versus placebo.
MEASUREMENTS: Fatal andnonfatalCHDandmortality.
RESULTS: In the placebo group, participants with a high
homocysteine level (n = 588) had a 1.8 higher risk (95%
confidence interval (CI) = 1.2–2.5, P = .001) of fatal and
nonfatal CHD than those with a low homocysteine level
(n = 597). The absolute risk reduction in fatal and nonfa-
tal CHD with pravastatin treatment was 1.6% (95%
CI = 1.6 to 4.7%) in the low homocysteine group and
6.7% (95% CI = 2.7–10.7%) in the high homocysteine
group (difference 5.2%, 95% CI = 0.11–10.3, P = .046).
Therefore, the number needed to treat (NNT) with
pravastatin for 3.2 years for benefit related to fatal and
nonfatal CHD events was 14.8 (95% CI = 9.3–36.6) for
high homocysteine and 64.5 (95% CI = 21.4–∞) for low
homocysteine.
CONCLUSION: In older persons at risk of CVD, those
with high homocysteine are at highest risk for fatal and
nonfatal CHD. With pravastatin treatment, this group has
the highest absolute risk reduction and the lowest NNT to
prevent fatal and nonfatal CHD. J Am Geriatr Soc
62:213–221, 2014.
Key words: homocysteine; older persons; cardiovascu-
lar risk; statins; prevention
The aim of cardiovascular risk management is toreduce the incidence of cardiovascular events in high-
risk populations. Clinical cardiovascular risk scores, such
as the Framingham Risk Score1 and the Systematic Coro-
nary Risk Evaluation (SCORE),2 are used worldwide to
select those with high cardiovascular risk, but their accu-
racy to predict risk of cardiovascular outcomes declines
with advancing age.3–6 Because the prevalence and inci-
dence of cardiovascular disease (CVD) increases exponen-
tially with age,7–9 some have suggested that preventive
treatment be offered to everyone over a specified age
without measuring other risk factors,10 but others empha-
size the need for risk stratification in old age.11,12
Recently, the Leiden 85-plus Study (and others) showed
that homocysteine is predictive of cardiovascular events in
old age.13–18
Because risk predictors are clinically meaningful only
when effective preventive treatment is available,19 which
treatment possibilities exist (and are appropriate) for
older persons with high homocysteine to lower their
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cardiovascular risk needs to be established. Large random-
ized controlled trials (RCTs) and meta-analyses show that
lowering plasma homocysteine using treatment with folate
has no beneficial effect on the incidence of cardiovascular
events.16,20,21 The PROspective Study of Pravastatin in the
Elderly at Risk (PROSPER)22 has shown that pravastatin
lowers the risk of coronary heart disease (CHD) in older
people in general, but not the risk of fatal or nonfatal
stroke. The current study was designed to determine
whether older persons with high homocysteine levels
would benefit more from this conventional preventive
treatment than those with lower levels.
A post hoc subanalysis was performed in PROSPER (a
large double-blind, randomized, placebo-controlled trial)
to assess the effect of pravastatin on CHD risk and mortal-
ity in older persons, stratified according to plasma level of
homocysteine.
METHODS
Study Design
The protocol of PROSPER has been published elsewhere.23
Briefly, in 1997 to 1999, 5,804 individuals were enrolled
in Scotland (n = 2,520), Ireland (n = 2,184), and the Neth-
erlands (n = 1,100). Men and women aged 70 to 82 were
recruited, with preexisting vascular disease (coronary, cere-
bral, or peripheral) or at risk of such disease because of
smoking, hypertension, or diabetes mellitus. Their plasma
total cholesterol was required to be 154 to 347 mg/dL
(4.0–9.0 mM) and their triglyceride concentrations 531
mg/dL or less (≤6.0 mM). Individuals with congestive
heart failure (New York Heart Association functional class
III or IV) or poor cognitive function (Mini-Mental State
Examination (MMSE) score <24 points) were excluded.
Participants were randomized to a group receiving 40 mg
of pravastatin a day or to a control group receiving pla-
cebo and were followed (on average) for 3.2 years.
Throughout the study, all study personnel were unaware
of the allocated study medication status of the partici-
pants. The institutional ethics review boards of all centers
approved the protocol, and all participants gave written
informed consent.
Determination of Homocysteine
After blood was drawn, blood samples were kept at room
temperature until they were processed in the laboratory to
be stored in the biobank (80°C). In 2010, homocysteine
concentrations were measured in the biobank ethylenedi-
aminetetraacetic acid plasma samples, from samples taken
at baseline (blood samples, n = 5,757; missing, n = 47) and
again at 6 months. Measurements were done in batches
after reduction to the free form with a fluorescence polariza-
tion immunoassay (IMx analyzer; Abbott, Abbott Park, IL).
The median plasma homocysteine level was 14.1 lM
(interquartile range (IQR) 11.8–17.0) in the Netherlands
(n = 1,100), 17.9 lM (IQR 15.3–21.8) in Scotland
(n = 2,505), and 18.8 lM (IQR 15.6–23.3) in Ireland
(n = 2,152), although there were differences in standard
operating procedures between the study sites. (The Dutch
and Scottish blood samples were processed within 8 hours,
whereas in Ireland, this processing frequently exceeded
8 hours.) Statistical analysis showed that the variance in
log homocysteine for Scotland and the Netherlands was
comparable (F = 2.4, P = .12), but both were significantly
different from Ireland (Scotland vs Ireland, F = 5.4,
P = .02; the Netherlands vs Ireland, F = 11.2, P = .001).
Because plasma homocysteine levels increase by 0.5 to
1.0 lM/h in blood at room temperature,24–26 differences
in lag time could explain the differences in variance
between Ireland and the other countries. Therefore, it was
decided to exclude participants from Ireland from this
analysis.
Outcomes
The outcomes, described in the design of PROSPER,23
were the incidence of fatal and nonfatal CHD (including
definite or suspected CHD mortality and nonfatal myocar-
dial infarction (MI)), nonfatal MI, CHD mortality, non-
CHD mortality, and all-cause mortality. The PROSPER
Endpoints Committee, which was blinded to study medica-
tion and plasma levels of homocysteine, assessed all CHD
endpoints.
Data Analysis
At baseline, participants were ranked in three groups equal
in size (low, medium, and high homocysteine) based on
plasma homocysteine level, sex, and study site. Within
each homocysteine group, the baseline characteristics of
the placebo and treatment groups were compared using
independent t-tests for continuous data and Pearson chi-
square tests (degrees of freedom (df) = 1) for categorical
data.
Predictive Value of Homocysteine in the Placebo Group
The cumulative incidence rates of fatal and nonfatal CHD
and all-cause mortality for the three homocysteine groups
were calculated using Kaplan–Meier curves and compared
using the log rank test (df = 2). Hazard ratios (HRs) and
corresponding 95% confidence intervals (95% CIs) for
sex- and study site–specific tertiles of homocysteine were
calculated for the endpoints using Cox proportional haz-
ard models (reference low homocysteine), with adjustment
for age. To further investigate the independent predictive
value of homocysteine, baseline history of CVD, baseline
Framingham risk factors (smoking, diabetes mellitus, left
ventricle hypertrophy, systolic blood pressure, total choles-
terol, high density lipoprotein cholesterol (HDL-C)), and
earlier published predictors in PROSPER (C-reactive pro-
tein (CRP), and creatinine clearance (Cockcroft-Gault))
were also adjusted for.
Treatment Effect Comparing the Placebo and
Treatment Groups
The treatment effects of pravastatin and placebo according
to homocysteine group were calculated using two methods.
First, according to homocysteine group, the cumulative
incidence rate for fatal and nonfatal CHD and all-cause
mortality are presented for those taking placebo and those
taking pravastatin with Kaplan–Meier curves and
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compared using the log rank test (df = 1) and Cox
proportional hazard models. No adjustments were made.
The presence of multiplicative interaction was formally
tested by adding the interaction term (treatment 9 homo-
cysteine group) to the Cox regression model. All analyses
were on an intention-to-treat basis.
Second, the absolute risk reduction according to
treatment with pravastatin was calculated. Differences in
absolute risk reductions between the homocysteine groups
were tested using a z-test. Numbers needed to treat
(NNT) to benefit were calculated over the mean follow-
up of the trial (3.2 years) based on the difference in
cumulative proportion surviving in the placebo and pra-
vastatin groups.27,28 Because creatinine clearance seems to
be associated with homocysteine levels, a subgroup analy-
sis for absolute risk reduction was conducted for fatal
and nonfatal CHD and for all-cause mortality in partici-
pants with creatinine clearance of 30 mL/min or greater.
Influence of Treatment with Pravastatin on
Homocysteine
To investigate whether pravastatin treatment influences
plasma homocysteine levels, homocysteine concentrations
were measured after 6 months of treatment for 1,832 par-
ticipants (183 taking placebo, 1,649 taking pravastatin).
The effect of pravastatin treatment on plasma homocyste-
ine levels was tested after 6 months using linear regression
analysis adjusted for baseline homocysteine.
RESULTS
In total, 3,620 PROSPER participants from the Nether-
lands and Scotland were eligible for this study. Because 15
participants had missing biobank samples, and 83 had
missing homocysteine measurements, 3,522 participants
(1,764 placebo, 1,758 pravastatin) were included in the
analyses. The cutoff values of the homocysteine tertiles
(33% and 67%) in the Netherlands (n = 1,049) were 11.7
and 14.7 lM, respectively, for women and 13.5 and
16.9 lM, respectively, for men; for Scotland (n = 2,473)
these limits were 15.4 and 19.6 lM, respectively, for
women, and 16.9 and 21.0 lM, respectively, for men.
Baseline Characteristics
Table 1 presents baseline characteristics of the total group
of participants and according to homocysteine group,
stratified for placebo or pravastatin. In the total group, the
mean age of participants was 75.3  3.4, and 48% had a
history of CVD. Mean homocysteine level at baseline was
18.3  7.1 lM. There were no differences according to
homocysteine group in baseline characteristics between the
pravastatin and placebo groups. The proportion of partici-
pants with diabetes mellitus was lower in the high homo-
cysteine group.
Predictive Value of Homocysteine in the Placebo Group
Figure 1 shows the cumulative incidence of fatal and non-
fatal CHD and all-cause mortality for the three homocy-
steine groups in the placebo group. Participants with
medium homocysteine levels had no greater risk of fatal
and nonfatal CHD than those with low homocysteine
(HR = 1.1, 95% CI = 0.76–1.6, P = .57), but those with
high homocysteine had a 1.8 times greater risk (95%
CI = 1.2–2.5, P = .001). For overall mortality, the HRs
were 1.0 (95% CI = 0.67–1.5, P = .99) and 1.7 (95%
CI = 1.2–2.5, P = .003), respectively. These estimates did
not change after additional adjustments for history of
CVD; Framingham risk factors; or CRP, HDL-C, and
creatinine clearance (data not shown).
Similarly, participants with high homocysteine levels
had a greater risk of nonfatal MI, CHD mortality, and
non-CHD mortality. Furthermore, no differences in risk
were found between the medium and low homocysteine
level groups for any of these outcomes (data not shown).
Treatment Effect Depending on Homocysteine
Figure 2 presents the cumulative incidence of fatal and
nonfatal CHD and all-cause mortality in participants with
and without pravastatin according to homocysteine group.
In participants with high homocysteine, an HR of 0.57
(95% CI = 0.41–0.81, P = .002) was found as the treat-
ment effect of pravastatin on fatal and nonfatal CHD, and
an HR of 0.70 (95% CI = 0.50–0.98, P = .04) as the
treatment effect on all-cause mortality. With medium and
low homocysteine levels, there was no significant differ-
ence in cumulative incidence between placebo and pravast-
atin treatment.
Moreover, multiplicative interaction was not found
between treatment and homocysteine group (fatal and
nonfatal CHD: P for multiplicative interaction = .208, all-
cause mortality: P for multiplicative interaction = .097;
Figure 2). Similar patterns were seen for nonfatal MI and
CHD mortality. For non-CHD mortality, no effect of
treatment with pravastatin was found in any of the three
homocysteine groups (data not shown).
Table 2 presents absolute treatment effects of pravast-
atin according to homocysteine group. The absolute risk
reduction in fatal and nonfatal CHD with pravastatin
treatment was 1.6% (95% CI = 1.6 to 4.7) in the low
homocysteine group and 6.7% (95% CI = 2.7–10.7) in the
high homocysteine group (absolute risk reduction differ-
ence = 5.2%, 95% CI = 0.11–10.3, P = .046). For all-
cause mortality, the absolute risk reductions were 0.66%
(95% CI = 4.0 to 2.7) and 4.6% (95% CI = 0.78–8.4),
respectively (absolute risk reduction difference = 5.2%,
95% CI = 0.19–10.3, P = .04).
Mean homocysteine values of 18.3 lM were found in
persons with creatinine clearance of 30 mL/min or greater
(n = 3,426) and of 19.0 lM (P = .29) in persons with cre-
atinine clearance of <30 mL/min (n = 96). Because creati-
nine clearance is known to be associated with
homocysteine level, a subgroup analysis was conducted in
persons with creatinine clearance of 30 mL/min or greater.
The differences in absolute risk reductions according to
pravastatin treatment remained similar (fatal and nonfatal
CHD 6.0%, 95% CI = 0.84–11.1, P = .02; all-cause mor-
tality 5.8%, 95% CI = 0.70–11.0, P = .03).
For fatal and nonfatal CHD, the NNT with pravasta-
tin to benefit for 3.2 years was 14.8 (95% CI = 9.3–36.6)
in the high homocysteine group, 81.3 (95% CI = 21.5–∞)
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in the medium homocysteine group, and 64.5 (95%
CI = 21.4–∞) in the low homocysteine group (high vs low,
P = .046) (Figure 3). For all-cause mortality, a beneficial
result was found in the high homocysteine group
(NNT = 21.8, 95% CI = 11.9–129) but no benefit in the
medium and low homocysteine groups (high vs low,
P = .04).
Influence of Pravastatin on Homocysteine
After 6 months of treatment, homocysteine levels had
fallen 0.52 lM (95% CI = 1.1 to 0.07) from baseline
for those on pravastatin (linear regression, P = .08).
DISCUSSION
This study suggests that homocysteine may be a promising
new CHD risk predictor in older people, because high
plasma homocysteine levels not only indicate older persons
at high risk for fatal and nonfatal CHD and all-cause mor-
tality, but also identify those with the highest absolute risk
reduction due to the use of pravastatin and the lowest
NNT to prevent fatal and nonfatal CHD.
Earlier studies showed that older persons with high
homocysteine levels are at greater risk of cardiovascular
events, and homocysteine level may provide additional risk
stratification beyond traditional risk factors.13–18 For
example, a previous study examined whether adding homo-
cysteine to a model based on traditional CVD risk factors
improved classification. In two younger population cohorts,
they found that addition of homocysteine level to Framing-
ham risk score significantly improved risk prediction.18
Moreover, for persons aged 85 and older, a previous study
showed that the classic risk factors as included in the
Framingham risk score no longer accurately predicted
Table 1. Baseline Participant Characteristics According to Treatment and Homocysteine Level (n = 3,522)
Characteristic All
Homocysteine Level
Low Medium High
Placebo,
n = 597
Pravastatin,
n = 575
Placebo,
n = 579
Pravastatin,
n = 598
Placebo,
n = 588
Pravastatin,
n = 585
Demographic and functional characteristics
Study site Scotland, n (%) 2,473 (70) 424 (71) 400 (70) 400 (69) 425 (71) 416 (71) 408 (70)
Male, n (%) 1,765 (50) 296 (50) 291 (51) 286 (49) 304 (51) 285 (49) 303 (52)
Age, mean  SD 75.3  3.4 74.9  3.4 74.9  3.3 75.2  3.2 75.2  3.3 75.6  3.5 75.7  3.4
Mini-Mental State Examination
score, mean  SD
28.2  1.5 28.3  1.4 28.3  1.4 28.3  1.4 28.2  1.5 28.1  1.5 28.0  1.6
Barthel index, mean SD 19.8  0.7 19.7  0.7 19.8  0.8 19.8  0.7 19.8  0.5 19.7  0.8 19.7  0.9
Instrumental activity of daily
living score, mean  SD
13.6  0.9 13.6  0.9 13.6  0.9 13.7  0.9 13.7  0.7 13.6  1.1 13.5  1.0
Clinical history and cardiovascular risk factors
History of cardiovascular
diseasea
1,675 (48) 267 (45) 272 (47) 269 (47) 279 (47) 298 (51) 290 (50)
History of diabetes mellitus 386 (11) 88 (15) 85 (15) 68 (12) 57 (9.5) 45 (7.7) 43 (7.4)
Creatinine clearance
<30 mL/minb
96 (2.7) 12 (2.0) 15 (2.6) 14 (2.4) 16 (2.7) 17 (2.9) 22 (3.8)
Body mass index, kg/m2,
mean  SD
27.0  5.5 26.9  5.6 26.9  5.5 27.3  5.7 27.0  5.3 27.2  5.6 26.8  5.4
Current smoker 943 (27) 157 (26) 137 (24) 156 (27) 166 (28) 167 (28) 160 (27)
Alcohol, U/wk, mean  SDc 5.3  8.4 4.9  7.3 5.0  7.5 5.5  8.7 5.6  9.5 4.9  7.7 5.7  9.4
Systolic blood pressure,
mmHg, mean  SD
154.7  21.4 153.4  20.6 154.1  21.1 156.0  20.5 154.2  21.2 155.4  23.1 155.2  21.6
Total cholesterol, mg/dL,
mean  SD
220.7  35.5 218.4  34.9 219.6  35.8 220.8  33.9 221.5  35.2 220.2  36.0 223.6  36.9
Low-density lipoprotein
cholesterol, mg/dL,
mean  SD
148.5  31.0 146.8  30.9 147.6  30.3 148.9  29.8 148.6  31.1 147.9  32.1 151.1  32.0
High-density lipoprotein
cholesterol, mg/dL,
mean  SD
49.2  13.4 49.8  12.6 48.8  13.0 49.2  13.0 49.3  13.1 49.2  14.5 49.3  14.1
Triglycerides, mg/dL,
mean  SD
136.5  61.2 131.4  59.1 138.2  63.4 136.1  58.5 140.4  66.2 136.5  60.8 136.5  58.4
Homocysteine, lM,
mean  SD
18.3  7.1 13.0  2.1 13.1  2.1 16.8  2.2 17.0  2.2 25.2  8.6 24.6  8.2
SD = Standard Deviation.
a Stable angina pectoris, intermittent claudication, stroke, transient ischemic attack, myocardial infarction, peripheral arterial disease surgery, or amputa-
tion for vascular disease ≥6 months before study entry.
b Calculated using the Cockroft-Gault formula.
c 1 U = 60 mL distilled spirits, 170 mL wine, or 300 mL beer.
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cardiovascular mortality in those with no history of CVD,
whereas a single measurement of homocysteine accurately
identified those at high risk of cardiovascular mortality.13
The findings of the current study not only confirm studies
reporting that homocysteine predicts CHD risk in old age,
but also show the independent predictive capacity in a
selected population of older persons with high cardiovascu-
lar risk. A recent metaanalysis showed that a moderate
homocysteine elevation due to genetic variance does not
meaningfully affect CHD risk.29 This finding indicates that
circulating homocysteine levels within the normal range are
not causally related to CHD risk. Moreover, large RCTs
and their meta-analyses show that lowering plasma homo-
cysteine by treatment with folate has no beneficial effect on
the incidence of cardiovascular events.16,20,21 Therefore,
the underlying biological pathway to explain the predictive
value of high homocysteine levels for CVD, if there is one,
is unknown. Homocysteine may be seen as an epiphenome-
non rather than a causal agent, but this does not refute its
predictive abilities.
Because homocysteine was found to be not causally
related to CVD, whether preventive treatment could be
offered to those with high homocysteine to reduce their
cardiovascular risk is unknown. In the Air Force/Texas
Coronary Atherosclerosis Prevention Study (AFCAPS/
TexCAPS),30 with only a small proportion of older
adults, the beneficial effect of statin treatment in people
with high homocysteine levels was limited to people with
a low-density lipoprotein cholesterol (LDL-C) level higher
than 149 mg/dL. There results further extend the findings
from the AFCAPS/TexCAPS by demonstrating that the
benefits of statin treatment may differ according to homo-
cysteine level in high-risk individuals with an average
LDL-C level of 148 mg/dL. If these findings hold true in
a subsequent study, there could be a role for measure-
ment of homocysteine levels to help guide decisions on
statin use in older adults, which is a widely available
treatment. This is an important criterion underlying
screening.19
The present study revealed other findings that deserve
further examination. First, although a clear CHD risk ben-
efit from pravastatin therapy over the trial period of
3.2 years was found only in older persons with high and
not those with low and medium homocysteine levels, a
multiplicative interaction for the treatment effect was not
found. Therefore, there is a possibility that pravastatin has
the same treatment effect in all three homocysteine groups,
although even when the relative treatment effect is similar
between these groups, those at highest absolute risk will
have the most benefit in terms of absolute risk reduction.
This absolute risk reduction and corresponding NNT is
important in clinical practice and guidelines, because it
indicates the number of persons who need to be treated to
prevent one event.
Second, the effect of pravastatin in the homocysteine
groups does not show a linear trend. A lack of power
because of a small number of events in the low and med-
ium homocysteine level groups could explain this finding,
so the possibility of random variation cannot be excluded,
although it is also possible that pravastatin therapy is
effective only in people with homocysteine levels greater
than a certain cutoff value. The possibility of absolute
cutoff values requires more in-depth study, investigated in
a population with consistent blood sampling and storage
procedures.
Third, it was found that plasma levels of homocyste-
ine did not change significantly with pravastatin treatment
over a 6-month period, although a small reduction was
Figure 1. Cumulative incidence of fatal and nonfatal coronary heart disease (CHD) and all-cause mortality depending on base-
line plasma levels of homocysteine in the placebo group (n = 1,764). HR = Hazard Ratio; CI = Confidence Interval: high versus
low homocysteine group, adjusted for age.
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Fatal and nonfatal CHD* All-cause mortality†
Low homocysteine
Medium homocysteine 
High homocysteine 
1,172 1,133 1,078 1,172 1,148 1,115
1,177 1,135 1,072 1,177 1,157 1,111
1,173 1,125 1,047 1,173 1,145 1,095
Figure 2. Cumulative incidence fatal and nonfatal coronary heart disease (CHD) and all-cause mortality depending on pravasta-
tin treatment, stratified according to plasma homocysteine level at baseline. *P for multiplicative interaction = .21, †P for multi-
plicative interaction = .10.
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seen. Further examination is needed to determine the effect
of pravastatin treatment on homocysteine levels. If pra-
vastatin does not affect homocysteine levels, homocysteine
measurement might be useful to evaluate the need for
continuing preventive cardiovascular therapy in persons
under pravastatin treatment.
For new biomarkers, others have investigated whether
high cardiovascular risk and corresponding benefit from
treatment can be predicted. A large-scale RCT31 and an
earlier analysis in PROSPER32 showed that baseline CRP
concentration predicts cardiovascular risk but not the rela-
tive CHD risk benefits of pravastatin therapy. Other analy-
ses in PROSPER showed that HDL-C33 and creatinine
clearance34 can predict benefit from pravastatin therapy
for prevention of fatal and nonfatal CHD, although a high
plasma homocysteine level remained predictive of a benefi-
cial effect of pravastatin even in persons with creatinine
clearance of 30 mL/min or greater. Furthermore, pravasta-
tin was more effective in preventing cardiovascular events
in those without diabetes mellitus.22 The current study
showed that adjustment for these predictors did not influ-
ence the predictive value of homocysteine. A next step is
to study the clinical value of homocysteine and other bio-
markers by comparing their predictive value in combina-
tion with treatment response to develop the most-effective
predictors of cardiovascular risk and treatment benefit.
This is particularly important because statins are not with-
out side effects or costs, and targeting those most at risk
and with the most to gain would be clinically and econom-
ically advantageous.
Strength and Limitations
This study was embedded in PROSPER, a large double-
blind, randomized, placebo-controlled trial in older
persons. This landmark clinical cardiovascular trial was
performed following guidelines of good clinical practice,
including endpoints that the Endpoint Committee uni-
formly assessed. Because homocysteine was assessed after
closure of the trial, plasma levels of homocysteine had no
influence on the study procedures, clinical treatment during
follow-up, or the decisions of the Endpoint Committee.
A limitation of this study is that PROSPER procedures
were not originally designed to collect optimal blood sam-
ples for the assessment of plasma homocysteine. Therefore,
data could be used from only two of the three PROSPER
study sites, although it is possible that some samples from
those two sites were stored at room temperature for up to
8 hours before they were processed in the laboratory. This
could have led to artificially high homocysteine plasma
levels and therefore to misclassification in a higher homocy-
steine group. Because it was assumed that the samples with
artificially high homocysteine levels are spread nondifferen-
tial in the population, this could have resulted in underesti-
mation of the differences in treatment effect by homocysteine
levels. Because it is also known that homocysteine levels
vary between countries,13,35,36 more studies are needed to
validate the absolute cutoff values of homocysteine to select
elderly adults at highest risk in clinical practice.
Moreover, data regarding the use of B vitamins, which
lower homocysteine levels, are not available. Another
Table 2. Absolute Effect of Treatment with Pravastatin on Cardiovascular Outcomes and Mortality After
3.2 Years According to Homocysteine Level
Outcomes and
Homocysteine Groupsa
Placebo Pravastatin
ARR (95% CI)
Difference in ARR
(vs Low) (95% CI) P-Valuebn
Cumulative Incidence
of Events,% (95% CI) n
Cumulative Incidence
of Events,% (95% CI)
Fatal and nonfatal CHD
Low 48 8.2 (6.0–10.5) 32 6.7 (4.5–8.9) 1.6 (1.6–4.7) Reference
Medium 54 9.9 (7.4–12.4) 47 8.7 (6.3–11.0) 1.2 (2.2–4.7) 0.32 (5.0–4.3) .89
High 76 15.9 (12.8–19.1) 47 9.2 (6.7–11.7) 6.7 (2.7–10.7) 5.2 (0.11–10.3) .046
Nonfatal MI
Low 29 5.1 (3.3–6.9) 26 5.6 (3.6–7.7) 0.5 (3.2–2.2) Reference
Medium 39 7.3 (5.1–9.5) 26 5.1 (3.2–7.0) 2.2 (0.73–5.0) 2.7 (1.3–6.7) .18
High 51 11.3 (8.5–14.1) 32 6.4 (4.3–8.5) 4.9 (1.4–8.4) 5.5 (1.0–9.9) .02
CHD mortality
Low 20 3.4 (1.9–4.9) 11 2.0 (0.83–3.2) 1.4 (–0.45–3.3) Reference
Medium 18 3.3 (1.8–4.7) 27 4.7 (3.0–6.4) 1.5 (3.7–0.83) 2.9 (5.8–0.08) .06
High 33 6.5 (4.4–8.6) 18 3.5 (1.9–5.1) 3.0 (0.35–5.6) 1.5 (1.7–4.8) .35
Non-CHD mortality
Low 25 4.8 (3.0–6.6) 31 6.9 (4.6–9.1) 2.1 (4.9–0.84) Reference
Medium 30 5.4 (3.5–7.3) 32 5.9 (3.9–7.8) 0.46 (3.2–2.3) 1.6 (2.4–5.6) .43
High 46 8.4 (6.1–10.7) 34 6.5 (4.4–8.5) 2.0 (1.2–5.1) 4.0 (0.24–8.2) .06
All-cause mortality
Low 45 8.0 (5.8–10.3) 42 8.7 (6.3–11.1) 0.66 (4.0–2.7) Reference
Medium 48 8.5 (6.2–10.8) 59 10.3 (7.8–12.8) 1.8 (5.2–1.6) 1.1 (5.9–3.6) .64
High 79 14.3 (11.4–17.2) 52 9.8 (7.3–12.2) 4.6 (0.78–8.4) 5.2 (0.19–10.3) .04
CI = Confidence Interval; CHD = Coronary Heart Disease.
a Group sizes: low: placebo n = 597, pravastatin n = 575; medium: placebo n = 579, pravastatin n = 598; high: placebo n = 588, pravastatin n = 585.
b P-value of difference in absolute risk reduction (ARR) compared with reference group low homocysteine estimated using z-test.
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limitation of this study is that the treatment-by-homocyste-
ine group multiplicative interaction was not significant,
although the difference in absolute risk reduction between
high and low homocysteine was significant (P = .046 for
fatal and nonfatal CHD and P = .04 for all-cause mortal-
ity). The possibility of a type 1 error from multiple
comparisons cannot be excluded.
It might also be seen as a limitation that these analy-
ses focused only on homocysteine level to predict CHD
risk and treatment effect, rather than investigating the etio-
logical mechanisms behind the findings. Predictive and
etiological studies will contribute to the further develop-
ment of cardiovascular risk management in older adults,
both on their own merits.
Implications
A recent analysis of cost-effectiveness of statin treatment
in primary care showed that, even in older adults, it is use-
ful to stratify for risk of cardiovascular outcomes.12 The
current study shows that homocysteine may predict CHD
risk in the PROSPER population of older adults with high
cardiovascular risks. As a consequence, individuals without
traditional risk factors and thus with the lowest risks were
excluded. Before these results can be implemented in cur-
rent guidelines, further research is needed to find a cutoff
value of homocysteine and confirm that high-risk older
adults with high homocysteine levels obtain more benefit
from pravastatin treatment. Moreover, whether homocy-
steine is useful in predicting benefits from pravastatin
treatment for low- or intermediate-risk older adults
remains to be investigated.
Homocysteine is a promising CHD risk predictor in
old age, not only because high plasma homocysteine iden-
tifies older adults at high risk of fatal and nonfatal CHD,
but also because those persons have the highest absolute
risk reduction with pravastatin treatment and the lowest
NNT to prevent fatal and nonfatal CHD. This is an
important step in the further development of CHD risk
stratification and treatment for older people.
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